So it’s a super exciting time for the field and I just gave a talk then on the different pathophysiological causes or endotypes of sleep apnea and how we’re developing algorithms to automatically detect these from our existing sleep studies and newer approaches. So we’ve now got the tools to be able to automatically get this information with ease from the routine information and what that’s unlocking for us is the ability to then target these various drugs that are emerging...
So it’s a super exciting time for the field and I just gave a talk then on the different pathophysiological causes or endotypes of sleep apnea and how we’re developing algorithms to automatically detect these from our existing sleep studies and newer approaches. So we’ve now got the tools to be able to automatically get this information with ease from the routine information and what that’s unlocking for us is the ability to then target these various drugs that are emerging. So the one that is here now is the injectable tirzepatide It’s the one that’s been studied so far and obese people with sleep apnea can roughly halve your sleep apnea severity in these one-year trials in these folks that obtain substantial weight loss with those incretin agents or in particular tirzepatide. There are other studies underway in that space but beyond that the first targeted therapy for sleep apnea known as AD109, it’s a combination of a noradrenergic agent and an anti-muscarinic to activate the muscles around the airway and reactivate those muscles that lose some of their tone as we go off to sleep. So the core mechanism that’s really causing sleep apnea. Those studies, the Phase III studies, two major Phase III studies showed positive top line results and are now with the FDA and awaiting outcomes as to their approval status in late February. So a very exciting time for the field and there are others, many others that are also targeting those different endotypes that are in development at various stages. So you know they’re the two closest obviously tirzepatide here and with the potential for the other targeted drug therapy to be here early next year. Look I think it’s just an exciting time for the field as these therapies are opening up. We’re understanding more about the different causes, the technology, being able to monitor people over the multiple nights in the home and use that information to really better define what’s going on for the individual and target the therapy including opening up targeted therapies, combination therapies I should say for the first time. You know it’s really exciting so we’re starting to move beyond this sort of one-size-fits-all model to a care model where we know why that individual is getting their sleep apnea and which treatment or treatments may be most appropriate for them based on their individual causes. So very exciting time for the field.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.